EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents

Rogelio Gómez-Escobedo, Domingo Méndez-Álvarez, Citlali Vázquez, Emma Saavedra iD, Karina Vázquez, Verónica Alcántara-Farfán, Joaquín Cordero-Martínez iD, Alonzo Gonzalez-Gonzalez iD, Gildardo Rivera iD, Benjamín Nogueda-Torres iD

Molecules · 2024

DOI: 10.3390/molecules29163796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Rogelio Gómez-Escobedo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico. Hauptthemen laut MEDLINE: Trypanocidal Agents, NADH, NADPH Oxidoreductases, Molecular Docking Simulation, Trypanosoma cruzi. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto Politécnico Nacional.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

American trypanosomiasis or Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects approximately 6–7 million people worldwide. However, its pharmacological treatment causes several uncomfortable side effects, causing patients’ treatment abandonment. Therefore, there is a need for new and better treatments. In this work, the molecular docking of nine hundred twenty-four FDA-approved drugs on three different sites of trypanothione reductase of T. cruzi (TcTR) was carried out to find potential trypanocidal agents. Finally, biological evaluations in vitro and in vivo were conducted with the selected FDA-approved drugs. Digoxin, alendronate, flucytosine, and dihydroergotamine showed better trypanocidal activity than the reference drugs benznidazole and nifurtimox in the in vitro evaluation against the trypomastigotes form. Further, these FDA-approved drugs were able to reduce 20–50% parasitemia in a short time in an in vivo model, although with less efficiency than benznidazole. Therefore, the results suggest a combined therapy of repurposed and canonical drugs against T. cruzi infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanocidal AgentsNADH, NADPH OxidoreductasesMolecular Docking SimulationTrypanosoma cruziChagas DiseaseAnimalsHumansUnited States Food and Drug AdministrationDrug ApprovalDrug Evaluation, PreclinicalUnited StatesMice

Stichwörter der Autor:innen

Chagas diseaseFDA drugsmolecular dockingrepositioningtrypanothione reductase

Substanzen

trypanothione reductaseTrypanocidal AgentsNADH, NADPH Oxidoreductases

Autor:innen und Institutionen

  • Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico.
  • Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
  • Departamento de Bioquímica, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México 14080, Mexico.
  • Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Nuevo León, General Escobedo 66050, Mexico.
  • Laboratorio de Bioquímica Farmacológica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico.

ORCID-Profile: Emma Saavedra, Joaquín Cordero-Martínez, Alonzo Gonzalez-Gonzalez, Gildardo Rivera, Benjamín Nogueda-Torres

Förderung

  • Instituto Politécnico Nacional

Zitieren

APA

Gómez-Escobedo, R., Méndez-Álvarez, D., Vázquez, C., Saavedra, E., Vázquez, K., Alcántara-Farfán, V., Cordero-Martínez, J., Gonzalez-Gonzalez, A., Rivera, G., & Nogueda-Torres, B. (2024). Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents. Molecules. https://doi.org/10.3390/molecules29163796

Vancouver

Gómez-Escobedo R, Méndez-Álvarez D, Vázquez C, Saavedra E, Vázquez K, Alcántara-Farfán V, et al. Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents. Molecules. 2024. doi:10.3390/molecules29163796

BibTeX
@article{GmezEscobedo2024,
  author = {Gómez-Escobedo, Rogelio and Méndez-Álvarez, Domingo and Vázquez, Citlali and Saavedra, Emma and Vázquez, Karina and Alcántara-Farfán, Verónica and Cordero-Martínez, Joaquín and Gonzalez-Gonzalez, Alonzo and Rivera, Gildardo and Nogueda-Torres, Benjamín},
  title = {Molecular Docking-Based Virtual Screening of FDA-Approved Drugs Using Trypanothione Reductase Identified New Trypanocidal Agents},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29163796}
}
Kostenlos starten →